Overview

* Inspire Medical ( INSP ) Q3 revenue rises 10% yr/yr, beating analyst expectations

* Company completed $50 mln share repurchase, indicating confidence in future growth

* Transition to Inspire V system progressing well with positive clinician feedback

Outlook

* Company reaffirms full-year revenue guidance of $900 mln to $910 mln

* Company raises full-year diluted net income per share guidance to $0.90-$1.00

* Company maintains full-year gross margin guidance at 84% to 86%

Result Drivers

* INSPIRE V SYSTEM - Transition to Inspire V system contributed to revenue growth and improved gross margin due to lower cost of goods sold

* POSITIVE CLINICIAN FEEDBACK - Inspire V system received positive feedback from clinicians, with 100% successful device implants and reduced surgical times

* INCREASED OPERATING EXPENSES - Operating expenses rose due to patient marketing and corporate costs, partially offset by reduced R&D

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $224.5 $220.46

Revenue mln mln (18

Analysts

)

Q3 Net $9.9 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Inspire Medical Systems Inc ( INSP ) is $125.00, about 42.3% above its October 31 closing price of $72.08

* The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 44 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)